The science of chemotherapy has been built upon
the seminal concepts arising from pioneering studies,
notably by Paul Ehrlich, carried out nearly 100 years
ago. The investigations conducted in the early
decades of this century were of major significance for
antiparasite chemotherapy as they resulted in the
discovery of a variety of drugs for treating human
and animal diseases. Derivatives of many of these
drugs are still being used today, which, it could be
claimed, reflects the outstanding success of the early
approaches. However, it also highlights the relatively
poor record of drug discovery in more recent
decades. While major advances were taking place in
the development of drugs and vaccines for bacterial,
fungal and viral diseases, the discovery of new drugs
for parasitic infections progressed relatively slowly.
It would be wrong, however, to give an impression
that there were no advances. The discovery of the
avermectins and praziquantel has had an enormous
impact on anthelmintic therapy, and new classes of
antiprotozoal drugs have been developed for both
prophylaxis and treatment of infections. Nevertheless, major
problems remain and for some
parasitic diseases the situation now is worse than it
was 20 years ago. Malaria is perhaps the best example
in this respect. The advent of chloroquine resistance
in Plasmodium falciparum has resulted in a major
public health problem. In addition, the increase in
importance of some diseases, notably those associated with
immunosuppression in AIDS, has again
highlighted the limitations of antiparasite chemotherapy. New
drugs are needed urgently for a number of parasitic diseases.